Unusual benefits of macromolecular shielding by polyethylene glycol for reactions at the diffusional limit: The case of factor VIIai and tissue factor

Matthew Stone, Stephen B Harvey, Walter Kisiel, Donald Foster, Gary L Nelsestuen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Protein modification with poly(ethylene glycol) (PEG) can prolong circulatory lifetime and lower protein antigenicity in an animal. These benefits may arise from the proposed mechanism of PEG action, molecular shielding of the protein surface, and lowered interaction with other macromolecules. Proteins that depend on macromolecule association for their function would not seem good targets for PEG modification as the benefits may be mitigated by loss of function. Indeed, high loss of function applied to PEG-modified factor VIIa and to active site-blocked blood clotting factors Xa or IXa was studied. A surprising finding was that PEG-modified, active site-blocked factor VIIa (PEG-VIIai, PEG-40 000) retained 40% of its function despite an 18-fold increase in circulatory lifetime. The discrepancy between functional loss and increased circulatory lifetime was consistent with a process that was limited by the diffusion step of assembly rather than the chemical binding step. The impact of PEG-40 000 on diffusion of VIIai is small (about 3-fold) relative to its potential impact on molecular shielding during the chemical binding step of association. These properties extended to a mutant of VIIai (P10Q/K32E, QE-VIIai) that has 25-fold higher function than wild-type factor VIIai. Overall, properties of PEG-modified proteins can suggest features of the kinetic mechanism and may provide enhanced proteins for anticoagulation therapy.

Original languageEnglish (US)
Pages (from-to)15820-15825
Number of pages6
JournalBiochemistry
Volume41
Issue number52
DOIs
StatePublished - Dec 31 2002

Fingerprint

Thromboplastin
Shielding
Polyethylene glycols
Factor VIIa
Proteins
Catalytic Domain
Factor IXa
Factor Xa
Blood Coagulation Factors
Ethylene Glycol
Blood Coagulation
Macromolecules
Membrane Proteins
Animals
Blood
Kinetics

Cite this

Unusual benefits of macromolecular shielding by polyethylene glycol for reactions at the diffusional limit : The case of factor VIIai and tissue factor. / Stone, Matthew; Harvey, Stephen B; Kisiel, Walter; Foster, Donald; Nelsestuen, Gary L.

In: Biochemistry, Vol. 41, No. 52, 31.12.2002, p. 15820-15825.

Research output: Contribution to journalArticle

@article{3c8835988f24421192611107e337cbbd,
title = "Unusual benefits of macromolecular shielding by polyethylene glycol for reactions at the diffusional limit: The case of factor VIIai and tissue factor",
abstract = "Protein modification with poly(ethylene glycol) (PEG) can prolong circulatory lifetime and lower protein antigenicity in an animal. These benefits may arise from the proposed mechanism of PEG action, molecular shielding of the protein surface, and lowered interaction with other macromolecules. Proteins that depend on macromolecule association for their function would not seem good targets for PEG modification as the benefits may be mitigated by loss of function. Indeed, high loss of function applied to PEG-modified factor VIIa and to active site-blocked blood clotting factors Xa or IXa was studied. A surprising finding was that PEG-modified, active site-blocked factor VIIa (PEG-VIIai, PEG-40 000) retained 40{\%} of its function despite an 18-fold increase in circulatory lifetime. The discrepancy between functional loss and increased circulatory lifetime was consistent with a process that was limited by the diffusion step of assembly rather than the chemical binding step. The impact of PEG-40 000 on diffusion of VIIai is small (about 3-fold) relative to its potential impact on molecular shielding during the chemical binding step of association. These properties extended to a mutant of VIIai (P10Q/K32E, QE-VIIai) that has 25-fold higher function than wild-type factor VIIai. Overall, properties of PEG-modified proteins can suggest features of the kinetic mechanism and may provide enhanced proteins for anticoagulation therapy.",
author = "Matthew Stone and Harvey, {Stephen B} and Walter Kisiel and Donald Foster and Nelsestuen, {Gary L}",
year = "2002",
month = "12",
day = "31",
doi = "10.1021/bi0204544",
language = "English (US)",
volume = "41",
pages = "15820--15825",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "52",

}

TY - JOUR

T1 - Unusual benefits of macromolecular shielding by polyethylene glycol for reactions at the diffusional limit

T2 - The case of factor VIIai and tissue factor

AU - Stone, Matthew

AU - Harvey, Stephen B

AU - Kisiel, Walter

AU - Foster, Donald

AU - Nelsestuen, Gary L

PY - 2002/12/31

Y1 - 2002/12/31

N2 - Protein modification with poly(ethylene glycol) (PEG) can prolong circulatory lifetime and lower protein antigenicity in an animal. These benefits may arise from the proposed mechanism of PEG action, molecular shielding of the protein surface, and lowered interaction with other macromolecules. Proteins that depend on macromolecule association for their function would not seem good targets for PEG modification as the benefits may be mitigated by loss of function. Indeed, high loss of function applied to PEG-modified factor VIIa and to active site-blocked blood clotting factors Xa or IXa was studied. A surprising finding was that PEG-modified, active site-blocked factor VIIa (PEG-VIIai, PEG-40 000) retained 40% of its function despite an 18-fold increase in circulatory lifetime. The discrepancy between functional loss and increased circulatory lifetime was consistent with a process that was limited by the diffusion step of assembly rather than the chemical binding step. The impact of PEG-40 000 on diffusion of VIIai is small (about 3-fold) relative to its potential impact on molecular shielding during the chemical binding step of association. These properties extended to a mutant of VIIai (P10Q/K32E, QE-VIIai) that has 25-fold higher function than wild-type factor VIIai. Overall, properties of PEG-modified proteins can suggest features of the kinetic mechanism and may provide enhanced proteins for anticoagulation therapy.

AB - Protein modification with poly(ethylene glycol) (PEG) can prolong circulatory lifetime and lower protein antigenicity in an animal. These benefits may arise from the proposed mechanism of PEG action, molecular shielding of the protein surface, and lowered interaction with other macromolecules. Proteins that depend on macromolecule association for their function would not seem good targets for PEG modification as the benefits may be mitigated by loss of function. Indeed, high loss of function applied to PEG-modified factor VIIa and to active site-blocked blood clotting factors Xa or IXa was studied. A surprising finding was that PEG-modified, active site-blocked factor VIIa (PEG-VIIai, PEG-40 000) retained 40% of its function despite an 18-fold increase in circulatory lifetime. The discrepancy between functional loss and increased circulatory lifetime was consistent with a process that was limited by the diffusion step of assembly rather than the chemical binding step. The impact of PEG-40 000 on diffusion of VIIai is small (about 3-fold) relative to its potential impact on molecular shielding during the chemical binding step of association. These properties extended to a mutant of VIIai (P10Q/K32E, QE-VIIai) that has 25-fold higher function than wild-type factor VIIai. Overall, properties of PEG-modified proteins can suggest features of the kinetic mechanism and may provide enhanced proteins for anticoagulation therapy.

UR - http://www.scopus.com/inward/record.url?scp=0037207114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037207114&partnerID=8YFLogxK

U2 - 10.1021/bi0204544

DO - 10.1021/bi0204544

M3 - Article

C2 - 12501211

AN - SCOPUS:0037207114

VL - 41

SP - 15820

EP - 15825

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 52

ER -